Role of fatty liver in metabolic syndrome;A zsírmáj szerepe a metabolikus szindróma kialakulásában

Orvosi Hetilap

Volumn 151, Issue 35, 2010, Pages 1430-1433

  Fodor, Miklós ^a  

^a Igazságügyi Pszichiáter Szakérto   (Hungary)

Author keywords

adipocyte hypertrophy and hyperplasia; fatty liver; insulin resistance; metabolic syndrome; obesity; type 2 diabetes; visceral adipose tissue

Indexed keywords

INSULIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; BODY WEIGHT; COMPLICATION; INTRAABDOMINAL FAT; METABOLISM;

BODY WEIGHT; FATTY LIVER; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; TRIGLYCERIDES;

EID: 77956299212     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28897     Document Type: Review

References (26)

1. Abhimanyu, G., Anoop., M.: Hepatic steatosis, insulin resistance, and adipose tissue disorders. J. Clin. Endocrinology & Metabol, 2002, 87, 3019-3022.
2. Angulo, P.: Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
3. Camp, H. S., Ren, D., Leff, T.: Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol. Med., 2002, 8, 442-447.
4. Deivanayagam, S., Mohammed, B. S., Vitola, B. E. és mtsai: Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am. J. Clin. Nutr., 2008, 88, 257-262.
5. Earls, F.: Prevalence of the metabolic syndrome defined by the International Diabetes Federation Among Adults in the U.S. Diabetes Care, 2005, 28, 2745-2749.
6. Ersoz, G.: Treatment of nonalcoholic steatohepatitis with Nacetylcysteine. (Abstract) Gastroenterology, 2000, 118, A1444.
7. Fabbrini, E., Magkos, F., Mohammed, S. és mtsai: Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. 2009, www.pnas.org./cgi/doi/1073/ pnas
8. Fabbrini, E., Sullivan, S., Klein, S.: Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology, 2010, 51, 679-689.
9. Frayn, K. N.: Visceral fat and insulin resistance curative or correlative? Br. J. Nutr., 2000, 83, S71-S77.
10. FeHé J., Németh E., Lengyel G.: A nem alkoholos steatohepatitis (NASH) a metabolikus szindróma? Orv. Hetil., 2004, 45, 1499-1506.
11. Glancz, J.: Intrahepatic cholestasis: a randomized controlled trial comparing dexamethason and ursodeoxycholic acid. Hepatology, 2005, 42, 1399-1405.
12. Hausman, D. B., DiGirolamo, M., Bartness, T. J.: The biology of white adipocyte proliferation. Obes. Rev., 2001, 2, 239-254.
13. Houten, S.: A liver revival featuring bile acids. J. Hepatol., 2007, 46, 539-540.
14. Jermendy G. Y., Bitter I.: Antipszichotikus terápia és metabolikus szindróma. OrvosTovábbképzö Szemle, különszam, 2005, 47-50.
15. Kirk, E., Reeds, D. N., Finck, B. N. és mtsai: Effects of acute and chronic calorie restriction on insulin action in obese men and women. Gastroenterology, 2009, 136, 1552-1560.
16. Korenblat, K., Fabbrini, E., Mohammed, B. S. és mtsai: Liver, muscle and adipose tissue insulin resistance is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology, 2008, 134, 1369-1375.
17. Korenblat, K., Fabbrini, E., Mohammed, B. S. és mtsai: Liver, muscle and adipose tissue insulin resistance is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology, 2008, 134, 369-1375.
18. Lindor, K. D., Kowdley, K. V., Luketic, V. A.: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009, 50, 808-814.
19. Marchesini, G., Marzocchi, R., Agostini, F. és mtsai: Nonalcoholic fatty liver disease and the metabolic syndrome. Current Op Lipidol. 2005, 16, 421-427.
20. Reaven, G. M.: The role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-1607.
21. Ravussin, E., Smith, S. R.: Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad. Sc., 2002, 967, 363-378.
22. Saksena, S., Tandoh, R. K.: Ursodeoxycholic acid in the treatment of liver diseases. Postgrad. Med. J., 1997, 73, 75-78.
23. Tandon, R., Belmaker, R. H., Gattaz, W. és mtsai: World Psychiatric Association Pharmacopsychiatry Section statement on comparativeness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research, 2008, 100, 20-38.
24. Unger, R. H.: Obesity protects against metabolic syndrome. Proceedings of the National Academy of Sciences, online 2010. 03. 08.
25. Unger, R. H.: Lipotoxic diseases. Annu Rev. Med., 2002, 53, 319-336.
26. Urich, E.: Inzulinrezisztencia-középpontban a zsírszövet. LAM, 2004, 14, 171-178.